Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium

This study has been completed.
Sponsor:
Collaborator:
Tibotec Pharmaceutical Limited
Information provided by:
International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier:
NCT00332995
First received: June 1, 2006
Last updated: August 31, 2009
Last verified: August 2009
History of Changes
  Purpose

This Phase I trial will assess the feasibility of using a vaginal ring to deliver the candidate microbicide dapivirine (TMC120) for 7 days. The study population will consist of 13 healthy, sexually abstinent women. Safety and tolerability will be assessed through clinical and laboratory assessments. Feasibility of drug delivery will be assessed by measuring dapivirine (TMC120) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma.


Condition Intervention Phase
HIV Infections
 Drug: dapivirine (TMC120) vaginal ring
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Double-blind, Randomized, Placebo Controlled Trial to Study Safety, Local and Systemic Availability of TMC120 From a Vaginal Ring.

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by International Partnership for Microbicides, Inc.:

Primary Outcome Measures:
  • Safety and tolerability of seven-day use of a vaginal ring containing dapivirine (TMC120).
  • Assess dapivirine (TMC120) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma during and after seven-day use of a vaginal ring containing dapivirine (TMC120).
Estimated Enrollment: 13
Study Start Date: July 2005
Estimated Study Completion Date: August 2005
  Eligibility
Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female, age 18-50 years
  • Willing and able to provide written informed consent
  • HIV-uninfected and otherwise healthy
  • Willing to abstain from sexual activity and from use of vaginal products while participating in the study
  • Currently using oral contraceptives for pregnancy prevention
  • Willing to use oral contraceptives as needed to avoid menstruation while taking part in this study

Exclusion Criteria:

  • History of allergy to TMC120 or to the constituents of the vaginal ring
  • History of diagnosis of and/or treatment for a sexually transmitted disease within the last three months
  • History of genital tract surgery within the last month
  • Currently pregnant or breastfeeding, or within two months of last pregnancy outcome
  • Currently or within one month of participating in any other clinical research study
  • Current vulvar or vaginal symptoms / abnormalities that could influence the study results
  • Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption
  • Current diagnosis of any genital infection
  • Smoking more than 10 cigarettes / day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00332995

Locations
Belgium
Drug Research Unit Gent
Gent, Belgium, 9000
Sponsors and Collaborators
International Partnership for Microbicides, Inc.
Tibotec Pharmaceutical Limited
Investigators
Principal Investigator: Dr. Luc Van Bortel University of Ghent
  More Information

No publications provided

Responsible Party: Zeda Rosenberg ScD, International Partnership for Microbicides
ClinicalTrials.gov Identifier: NCT00332995     History of Changes
Other Study ID Numbers: IPM008, TMC120-C131
Study First Received: June 1, 2006
Last Updated: August 31, 2009
Health Authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
European Union: European Medicines Agency

Keywords provided by International Partnership for Microbicides, Inc.:
HIV Seronegativity

ClinicalTrials.gov processed this record on February 27, 2015